Israeli company Atox Bio Ltd. has reported a successful clinical trial of its AB103 treatment for Necrotizing Soft-Tissue Infection (NSTI). Financial magazine Globes reports that due to the successful trial, that has shown that the drug was both effective and safe, the company has begun raising millions of dollars. NSTI is a life-threatening bacterial infection with significant morbidity and high mortality rate.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments